The average list price of Wegovy (the only semaglutide-based drug currently approved for obesity) is around $1,300 a month, while Ozempic (approved for diabetes but sometimes prescribed off-label for weight loss) is around $1,000 monthly
GLP-1 agonist medications have revolutionized weight loss, enabling many people to lose a substantial amount of body fat and improve their health
mbgs eye health+ delivers five science-backed botanical bioactives, including astaxanthin, lutein, zeaxanthin, maqui berry, and saffron to protect your eyes and promote visual performance
Kauzman A, Pavone M, Blanas N, Bradley G
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
DOI: 10.1519/R-19785.1 Cavallini G, Biagiotti G, Koverech A, Vitali G